Industry Laments UK Decision To Go Ahead With ‘Unprecedented’ Sales Repayments
Executive Summary
The UK government has confirmed plans to raise payments made by drug companies in the statutory scheme for branded medicines to 24.4% for 2023, despite clear warnings from industry that the approach is unsustainable and jeopardizes the delivery of the government's ambitions for life sciences in the post-Brexit UK.
You may also be interested in...
Capacity Challenges Prompt NICE To Consider Secondees From Consultancy Firms
England’s health technology assessment institute is exploring solutions to help deal with its increased workload, high staff turnover and challenges in recruiting people with the expertise needed.
UK Industry Attacks Government’s ‘Unsustainable’ Repayment Proposals
Questions are being raised about the credibility of the UK’s voluntary and statutory drug pricing schemes because of uncertainty over the payment percentages companies will have to pay in future.
2021: A Record-Breaking Year For ‘Smart’ Pricing And Access Deals In England
NHS England and Improvement (NHSE&I) agreed 16 pricing and access deals with drug companies in 2021, ten of which can be considered ‘smart.’ The fact that these were achieved against a backdrop of COVID-19 is seen as impressive.